ABLC data

In a multicenter, randomized U.S. Phase III trial of 231 patients with invasive candidiasis, ABLC was shown to be as effective as conventional formulation of ampho-tericin B, but significantly less nephrotoxic.

Response rates were similar between those receiving ABLC and those receiving conventional drug - 65 percent versus 61 percent. Rates of mycological eradication also were similar - 88 percent versus 87 percent, ...